ALMS — Alumis Inc. stock price, charts and financials

QT77Alumis Inc.

Alumis Inc. (NASDAQ: ALMS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
26.12
-2.13-7.54%
OverviewShort InterestFilings
ALMSQT77Alumis Inc.·NASDAQ
26.12-7.54%
TA
Loading chart...
Screen all →
LEGN+2.48%$19.01RCUS-2.02%$27.62TNGX+0.11%$27.21TLX+1.31%$10.02IDYA-0.28%$35.40ADPT+2.39%$23.11ORKA-1.78%$94.79ARQT-3.43%$25.94
Snapshot
Index-P/E-EPS (ttm)-1.92Insider Own31.84%Shs Outstand123.43MPerf Week0.89%
Market Cap3.49BForward P/E-EPS next Y-2.73Insider Trans-0.01%Shs Float85.84MPerf Month6.04%
Enterprise Value3.46BPEG-EPS next Q-Inst Own-Short Float7.88%Perf Quarter14.42%
Income-234.32MP/S-EPS this Y-48.77%Inst Trans-Short Ratio4.99Perf Half Y5.25%
Sales8.40MP/B6.23EPS next Y4.28%ROA-35.35%Short Interest6.76MPerf YTD189.45%
Book/sh-P/C-EPS next 5Y-ROE-54.63%52W High28.99 -9.89%Perf Year589.02%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-71.89%52W Low3.48 651.33%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin89.63%Volatility6.93% 6.56%Perf 5Y-
Dividend TTM-EV/Sales-EPS Y/Y TTM62.24%Oper. Margin-5364.02%ATR (14)1.84Perf 10Y-
Dividend Ex-Date-Quick Ratio7.51Sales Y/Y TTM-Profit Margin-2825.70%RSI (14)54.08Recom2.13
Dividend Gr. 3/5Y-Current Ratio7.51EPS Q/Q59.34%SMA20-0.14%Beta1.36Target Price39.17
Payout0.00%Debt/Eq0.06Sales Q/Q-88.24%SMA5013.15%Rel Volume1.02Prev Close28.25
Employees223LT Debt/Eq0.11EarningsAug 12SMA20041.44%Avg Volume1.30MPrice26.12
IPO DateJun 28, 2024Option/ShortYes / YesEPS/Sales Surpr.0.37% -15.41%Net Debt/EBITDA0.07Volume1,320,830Change-7.54%
Analyst Ratings
DateActionAnalystRatingTarget
May-19-26ReiteratedChardan CapitalBuy$37 → $40
May-15-26ReiteratedMorgan StanleyOverweight$38 → $39
May-15-26ReiteratedWells FargoOverweight$39 → $51
May-15-26ReiteratedGuggenheimBuy$32 → $34
May-15-26DowngradeHC Wainwright & Co.Buy → Neutral$40 → $25
Mar-10-26ReiteratedRaymond James$46
Jan-21-26InitiatedChardanBuy$37
Jan-21-26ReiteratedLoop Capital Markets$37
Jan-09-26ReiteratedHC Wainwright & Co.Buy$20 → $40
Jan-07-26ReiteratedGuggenheimBuy$32
Latest News
Company

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue24000
Cost of Goods Sold Incl. D&A3300
Gross Profit21-300
Selling, General and Administrative Excl. Other92352013
Research and Development386266138101
Other Operating Expense-30-300
Operating Income-427-301-158-114
Interest Expense
0000
Unusual Expense
————
Non-Operating Income (Expense)175732
Net Income Before Taxes-252-294-155-112
Income Taxes-9000
Consolidated Net Income-243-294-155-112
Net Income From Continuing Operations-243-294-155-112
Net Income-243-294-155-112
EPS (Recurring)-2.32-10.38-2.99-14.93
EPS (Basic, Before Extraordinaries)-2.32-10.38-2.99-14.93
EPS (Diluted)-2.32-10.38-2.99-14.93
EBITDA-248-291-154-112
Other After Tax Adjustments
————
Stock Option Compensation Expense
————
Price To Earnings Ratio
————
Price To Sales Ratio345.67———
Gross Margin87.50———
Operating Margin-1,779.17———
Net Margin-1,012.50———
Shares Outstanding85028527
Market Capitalization8,296220——
Operating Lease Expense
————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$34.42$25.49$16.55$7.61$-1.33● Close Price0.00M7.75M15.50M23.25M31.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Pangali SanamChief Legal OfficerJul 06 '26Sale28.005,000140,00011,111Jul 08
Pangali SanamChief Legal OfficerJul 06 '26Option Exercise5.065,00025,30016,111Jul 08
Drappa JornChief Medical OfficerMay 22 '26Option Exercise6.6526,852178,64959,339May 27
AKKARAJU SRINIVASDirectorJan 09 '26Buy17.00588,2359,999,9951,853,488Jan 13
Foresite Labs, LLC10% OwnerJan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12
Foresite Capital Management VI LLC10% OwnerJan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12
Tananbaum James B.director, 10 percent owner:Jan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12
AKKARAJU SRINIVASDirectorDec 05 '25Buy9.84186,3771,833,7601,265,253Dec 09
AKKARAJU SRINIVASDirectorDec 04 '25Buy8.1866,027540,1011,078,876Dec 04
AKKARAJU SRINIVASDirectorDec 03 '25Buy7.75100,000775,0001,012,849Dec 04
AKKARAJU SRINIVASDirectorDec 02 '25Buy7.5596,000724,800912,849Dec 04
AKKARAJU SRINIVASDirectorDec 01 '25Buy7.4686,350644,171816,849Dec 01
AKKARAJU SRINIVASDirectorNov 28 '25Buy7.6438,702295,683730,499Dec 01
AKKARAJU SRINIVASDirectorNov 26 '25Buy7.6448,537370,823691,797Dec 01
Foresite Capital Management VI LLC10% OwnerNov 21 '25Buy7.3872,212532,9252,614,215Nov 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.